{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-23-000050","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.309683+00:00","generated_at":"2026-06-15T06:18:08.753155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sera Prognostics Q1 revenue $100K, net loss $10.6M; AVERT trial positive","bullets":["Revenue $100K, up 163% from $38K in Q1 2022.","Net loss narrowed to $10.6M from $12.2M YoY.","Cash and securities $100M; R&D spend $4.1M (up), SG&A $7.3M (down).","Positive AVERT PRETERM TRIAL topline results announced in February.","Physician orders increasing; PRIME study interim look expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-23-000050","json":"https://secwatch.observer/filing/0001534969-23-000050.json","markdown":"https://secwatch.observer/filing/0001534969-23-000050.md","text":"https://secwatch.observer/filing/0001534969-23-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000050/0001534969-23-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000050/sera-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:18:08.753155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"792e43757f148e1e68f409ec7773905e3c1f469d","claim":"SERA PROGNOSTICS, INC. reported the first quarter of 2023 ended March 31, 2023 results: revenue $100,000, net income $10.6 million loss.","evidence_excerpt":"should serve as an additional catalyst to help us expand the use of our PreTRM Test and to increase revenue.” First Quarter 2023 Financial Results First quarter 2023 revenue of $100,000 compared to $38,000 for the same period of 2022. Total operating expenses were $11.4 million, down from $12.3 million for the first quarter of 2022. Research and development","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000050/0001534969-23-000050-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023 ended March 31, 2023"},{"label":"Revenue","value":"$100,000"},{"label":"Net income","value":"$10.6 million loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}